Strong sales of cancer, eye treatments help biotech giant beat analyst expectations by a nickel.
|
The Merck subsidiary has yeast that can copy human cell chemistry.
|
Traditionally the home turf of biotech companies, big pharma is making strides in developing new cancer drugs.
|
Lymphoma drug from Genentech, Biogen, and Roche OK'd for rheumatoid arthritis.
|
Biotech firm GlycoFi shows that yeast can improve drug function by helping control the drug’s molecular structure.
|
Biotech firm wants to sell its anti-blindness treatment, Lucentis.
|
Strong quarterly Herceptin and Avastin sales cause biotech giant shares to soar.
|
U.S. patent office rejects pharma giant's antibody-manufacturing methods patent.
|
Myrtle Potter brings Genentech’s drugs into the public eye.
|
Positive Tysabri and Rituxan data is announced; MicroRNAs have a role in cancer; valve replacement surgery is live on the web; and Canadian researchers develop human embryonic stem cell lines.
|
Genentech sees a 61 percent increase in net income for the first quarter, but the full-year outlook disappoints some.
|
Lucky for drug companies, we’re desperate to live – and look good – for a long, long time.
|